The activation of alternative transcriptional programs via the MLL3/4-UTX complex [12,35] can trigger dynamic shifts in KMT2A oncoprotein binding, which may activate non-canonical lineage programs, such as transitioning from a lymphoid to a myeloid lineage, contributing to leukemia’s ability to resist therapy [36]. The gene discussed is KMT2A; the disease is leukemia.